ArticleMultiple sclerosis journal - experimental, translational and clinical

A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis.

Andrew Eisen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.